Table II.

Baseline characteristics of childhood brain tumor survivors eligible for donepezil (n=11)

Sex
Male	6 (55%)
Race
White	10 (91%)
Asian	1 (9%)
Age at study enrollment (years)*	11.1 (9.3–17.3)
Parent education#
High School or less	3 (27%)
High school + some college	8 (73%)
Annual household Income#
<20,000	1(8%)
20–34,999	3 (25%)
35,000–49,999	2 (17%)
75,0000+	5(45%)
Parent marital status (married)#	7 (63%)
Diagnosis
Medulloblastoma	7
Craniopharyngioma	1
Pilocytic astrocytoma	1
Ependymoma	1
Pineoblastoma	1
Age at cranial RT*	5.55 (3.4–13.2)
Cranial RT Dose (Gy)*	55.8 (50.4–60.3)
Median time since radiation (years)	4.7 (1.9–11.9)
Chemotherapy treatment
Yes	8 (73%)
Lansky/Karnofsky performance status	90 (70–100)
Endocrinopathy##
GH deficiency	7 (64%)
Cortisol deficiency	3 (27%)
Hypothyroidism	7 (64%)
VP shunt	2 (18%)
Cranial nerve deficit	7 (64%)
Gross motor deficit	6 (55%)

^*Median and range;

^#based on CHRIS demographics;

RT= radiation therapy;

^**Mean(sd) Intelligence quotient (IQ) measured by Weschler Abbreviated Scale of Intelligence(WASI)(44);

^##Patients on hormone replacement therapy at time of study